CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
First successful CAR-T cell therapy for acute myeloid leukemia opens a new treatment path for a disease lacking approved cellular therapies.
This study reports the first clinical application of CD7-directed CAR-T cell therapy in patients with relapsed or refractory CD7+ AML, a disease with no currently approved cellular therapy. Published in Leukemia, the findings establish proof-of-concept for CAR-T expansion into AML beyond the B-cell malignancy space where CAR-T therapies have been approved.
What the study was
- Study design
- prospective_cohort
- Population
- Relapsed or refractory CD7-positive AML patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
High-priority: AML is a Pulse core topic with significant unmet need in the r/r setting; CD7 CAR-T is a genuinely novel approach in AML; Leukemia is a top-tier hematology journal indicating rigorous peer review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.